Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXCITE for locally advanced rectal cancer
ISRCTN86285819Phase 2Completed
- Sponsor
- University College London
- Start
- Mar 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, capecitabine and irinotecan in rectal cancer and rectal adenocarcinoma, sponsored by University College London. Primary endpoint: Histologically confirmed R0 resection rate. Started Mar 2009; status: completed.
02
Drugs
cetuximabcapecitabineirinotecan
03
Conditions
rectal cancerrectal adenocarcinoma
Beyond the preview
Go deeper on ISRCTN86285819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN86285819.